A shared comparison of diabetes mellitus and neurodegenerative disorders.


Journal

Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768

Informations de publication

Date de publication:
09 2019
Historique:
received: 06 11 2017
accepted: 29 10 2018
pubmed: 20 12 2018
medline: 19 6 2020
entrez: 20 12 2018
Statut: ppublish

Résumé

Diabetes mellitus (DM), one of the most prevalent metabolic diseases in the world population, is associated with a number of comorbid conditions including obesity, pancreatic endocrine changes, and renal and cardio-cerebrovascular alterations, coupled with peripheral neuropathy and neurodegenerative disease, some of these disorders are bundled into metabolic syndrome. Type 1 DM (T1DM) is an autoimmune disease that destroys the insulin-secreting islet cells. Type 2 DM (T2DM) is diabetes that is associated with an imbalance in the glucagon/insulin homeostasis that leads to the formation of amyloid deposits in the brain, pancreatic islet cells, and possibly in the kidney glomerulus. There are several layers of molecular pathologic alterations that contribute to the DM metabolic pathophysiology and its associated neuropathic manifestations. In this review, we describe the general signature metabolic features of DM and the cross-talk with neurodegeneration. We will assess the underlying molecular key players associated with DM-induced neuropathic disorders that are associated with both T1DM and T2DM. In this context, we will highlight the role of tau and amyloid protein deposits in the brain as well in the pancreatic islet cells, and possibly in the kidney glomerulus. Furthermore, we will discuss the central role of mitochondria, oxidative stress, and the unfolded protein response in mediating the DM-associated neuropathic degeneration. This study will elucidate the relationship between DM and neurodegeneration which may account for the evolution of other neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease as discussed later.

Identifiants

pubmed: 30565720
doi: 10.1002/jcb.28094
doi:

Substances chimiques

Amyloidogenic Proteins 0
tau Proteins 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14318-14325

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Mahmoud Morsi (M)

Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Firas Kobeissy (F)

Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Sameh Magdeldin (S)

Proteomics and Metabolomics Unit, Basic Research, Children's Cancer Hospital, Cairo, Egypt.
Physiology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.

Ahmed Maher (A)

Zoonotic Diseases Department, National Research Center, Dokki, Egypt.

Omnia Aboelmagd (O)

Faculty of Medicine, Cairo University, Cairo, Egypt.

Dina Johar (D)

Department of Biochemistry and Nutrition, Faculty of Women for Arts, Sciences and Education, Ain Shams University, Cairo, Egypt.
Department of Physiology and Pathophysiology, Faculty of Health Sciences, Rady College of Medicine, Max Rady University of Manitoba, Winnipeg, Canada.

Larry Bernstein (L)

Triplex Consulting, Northampton, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH